Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML
Sign Up to like & getrecommendations! Published in 2022 at "In Vivo"
DOI: 10.21873/invivo.12872
Abstract: Background/Aim: The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting agent has achieved approval. To… read more here.
Keywords: bet; mivebresib abbv; abbv 075; clinical modeling ... See more keywords